Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.157
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Intrathecal Trastuzumab: Immunotherapy Improves the Prognosis of Leptomeningeal Metastases in HER-2+ Breast Cancer Patient

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer

Effective Pharmacotherapy
2019English

Resource Utilization and Cost Saving Analysis of Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer Patients

Oncotarget
Oncology
2017English

Pcn163 - Cost-Effectiveness of Add-On Pertuzumab Combined With Trastuzumab and Docetaxel Versus Placebo as Treatment of Her-2 Positive Metastatic Breast Cancer in Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Targeting HER-2 in Gastric Cancer &Ndash; Incorporation of Trastuzumab Into the Treatment of Operable Disease

Gastrointestinal Cancer: Targets and Therapy
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy